ArticleJournal of cellular and molecular medicine2015
GFAP and antibodies against NMDA receptor subunit NR2 as biomarkers for acute cerebrovascular diseases.
Article in Journal of cellular and molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Antibodies against neuronal surface antigens in acute stroke: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Multi-Level Biomarkers for Early Diagnosis of Ischaemic Stroke: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Scalable Bio Marker Combinations for Early Stroke Diagnosis: A Systematic Review.Frontiers in neurology · 2021Pooled it
- Arterial Stiffness and Anti-NR2/GluN2 Autoantibodies to N-Methyl-D-Aspartate Receptors as Markers of Vascular Aging and Cognitive Impairment in Arterial Hypertension.Life (Basel, Switzerland) · 2026Article
- Changes in NR2ab Antibody Levels in the Blood of Patients Depending on their Condition: Acute or Chronic Cerebral Ischaemia.Acta medica Lituanica · 2026Article
- Elevated Levels of Serum Biomarkers Associated with Damage to the CNS Neurons and Endothelial Cells Are Linked with Changes in Brain Connectivity in Breast Cancer Patients with Vestibulo-Atactic Syndrome.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023Article
- Increasing miR-126 Can Prevent Brain Injury after Intracerebral Hemorrhage in Rats by Regulating ZEB1.Contrast media & molecular imaging · 2022Article
- Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients.Journal of neurotrauma · 2021Review
- Blood Biomarkers for Stroke Diagnosis and Management.Neuromolecular medicine · 2019Review
- Peripheral biomarkers of stroke: Focus on circulatory microRNAs.Biochimica et biophysica acta · 2016Review
- Biomarkers for acute diagnosis and management of stroke in neurointensive care units.Brain circulationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We studied whether the serum levels of glial fibrillary acidic protein (GFAP) and of antibodies against the N-methyl-d-aspartate receptor subunit NR2 (NR2 RNMDA ) can discriminate between intracerebral haemorrhage (ICH) and ischaemic stroke (IS) in stroke patients. We prospectively recruited patients with suspected stroke (72 confirmed) and 52 healthy controls. The type of brain lesion (ICH or IS) was established using brain imaging. The levels of GFAP and of antibodies against NR2 RNMDA were measured in blood samples obtained within 12 hrs after stroke onset and 24, 48 and 72 hrs and 1 and 2 weeks later using ELISA immunoassay. Improvement in diagnostic performance was assessed in logistic regression models designed to predict the diagnosis and the type of stroke. GFAP peaks early during haemorrhagic brain lesions (at significantly higher levels), and late in ischaemic events, whereas antibodies against NR2 RNMDA have significantly higher levels during IS at all time-points. Neither of the two biomarkers used on its own could sufficiently discriminate patients, but when they are used in combination they can differentiate at 12 hrs after stroke, between ischaemic and haemorrhagic stroke with a sensitivity and specificity of 94% and 91%, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.